1. |
Uhlig HH. Monogenic diseases associated with intestinal inflammation: Implications for the understanding of inflammatory bowel disease. Gut 2013;62:1795-805.
|
2. |
Macer BJ, Prady SL, Mikocka-Walus A. Antidepressants in inflammatory bowel disease: A systematic review. Inflamm Bowel Dis 2017;23:534-50.
|
3. |
Zaeem Sibtain D, Uppal ST, Sumalani KK, Qaiser MA, Mahmood Q, Butt N. Inflammatory bowel disease in developing world: Prevalence, clinical presentations, diagnostic and therapeutic challenges. Ann Roman Soc Cell Biol 2021;25:1092-102.
|
4. |
Chaleshi V, Safari MT, Tarban P, Nourian M, Balaii H, Shahrokh S, et al. Evaluation of IL-17B and IL-17F mRNA expression in peripheral blood mononuclear cells and association with clinical outcome of IBD Patients. Gastroenterol Hepatol Bed Bench 2017;10:S79-80.
|
5. |
Kaplan GG. The global burden of IBD: From 2015 to 2025. Nat Rev Gastroenterol Hepatol 2015;12:720-7.
|
6. |
Windsor JW, Kaplan GG. Evolving epidemiology of IBD. Curr Gastroenterol Rep 2019;21:1-9.
|
7. |
Cosnes J, Gower–Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140:1785-94.e4.
|
8. |
Olfatifar M, Zali MR, Pourhoseingholi MA, Balaii H, Ghavami SB, Ivanchuk M, et al. The emerging epidemic of inflammatory bowel disease in Asia and Iran by 2035: A modeling study. BMC Gastroenterol 2021;21:1-8.
|
9. |
Geboes K. Histopathology of Crohn's disease and ulcerative colitis. InflammBowel Dis 2003;4:210-28.
|
10. |
DeRoche TC, Xiao S-Y, Liu X. Histological evaluation in ulcerative colitis. Gastroenterol Rep 2014;2:178-92.
|
11. |
Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: Mucosal immune cells in intestinal inflammation. Gut 2013;62:1653-64.
|
12. |
Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell 2015;160:447-60.
|
13. |
Sartor RB, Mazmanian SK. Intestinal microbes in inflammatory bowel diseases. Am J Gastroenterol Suppl 2012;1:15-21.
|
14. |
Nourian M, Chaleshi V, Pishkar L, Azimzadeh P, Baradaran Ghavami S, Balaii H, et al. Evaluation of tumor necrosis factor (TNF)-α mRNA expression level and the rs1799964 polymorphism of the TNF-α gene in peripheral mononuclear cells of patients with inflammatory bowel diseases. Biomed Rep 2017;6:698-702.
|
15. |
Graham DB, Xavier RJ. Pathway paradigms revealed from the genetics of inflammatory bowel disease. Nature 2020;578:527-39.
|
16. |
Hyams JS, Thomas SD, Gotman N, Haberman Y, Karns R, Schirmer M, et al. Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): A multicentre inception cohort study. Lancet 2019;393:1708-20.
|
17. |
Boland BS, He Z, Tsai MS, Olvera JG, Omilusik KD, Duong HG, et al. Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses. SciImmunol2020;5.
|
18. |
Paludan SR, Pradeu T, Masters SL, Mogensen TH. Constitutive immune mechanisms: Mediators of host defence and immune regulation. Nat Rev Immunol 2021;21:137-50.
|
19. |
Flajnik MF, Kasahara M. Origin and evolution of the adaptive immune system: Genetic events and selective pressures. Nat Rev Gen 2010;11:47-59.
|
20. |
Joosten LA, Abdollahi-Roodsaz S, Dinarello CA, O'neill L, Netea MG. Toll-like receptors and chronic inflammation in rheumatic diseases: New developments. Nat Rev Rheumatol 2016;12:344-57.
|
21. |
Takeda K, Kaisho T, Akira S. Toll-like receptors. AnnRevImmunol 2003;21:335-76.
|
22. |
Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. NatImmunol 2001;2:947-50.
|
23. |
Kordjazy N, Haj-Mirzaian A, Haj-Mirzaian A, Rohani MM, Gelfand EW, Rezaei N, et al. Role of toll-like receptors in inflammatory bowel disease. Pharmacol Res 2018;129:204-15.
|
24. |
Lu Y, Li X, Liu S, Zhang Y, Zhang D. Toll-like receptors and inflammatory bowel disease. FrontImmunol 2018;9:72.
|
25. |
Hug H, Mohajeri MH, La Fata G. Toll-like receptors: Regulators of the immune response in the human gut. Nutrients 2018;10:203.
|
26. |
Levin A, Shibolet O. Toll-like receptors in inflammatory bowel disease-stepping into uncharted territory. World J Gastroenterol 2008;14:5149-53.
|
27. |
Jenks SA, Cashman KS, Zumaquero E, Marigorta UM, Patel AV, Wang X, et al. Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity 2018;49:725-39.e6.
|
28. |
Heger L, Balk S, Lühr JJ, Heidkamp GF, Lehmann CH, Hatscher L, et al. CLEC10A is a specific marker for human CD1c+dendritic cells and enhances their toll-like receptor 7/8-induced cytokine secretion. Front Immunol 2018;9:744.
|
29. |
Takeda K, Akira S. Toll-like receptors in innate immunity. IntImmunol2005;17:1-14.
|
30. |
Coelho T, Mossotto E, Gao Y, Haggarty R, Ashton JJ, Batra A, et al. Immunological profiling of paediatric inflammatory bowel disease using unsupervised machine learning. J Pediatr Gastroenterol Nutr 2020;70:833-40.
|
31. |
Sheehan D, Shanahan F. The gut microbiota in inflammatory bowel disease.Gastroenterol ClinNorth Am2017;46:143-54.
|
32. |
Kozłowska E, Agier J, Wysokiński A, Łucka A, Sobierajska K, Brzezińska-Błaszczyk E. The expression of toll-like receptors in peripheral blood mononuclear cells is altered in schizophrenia.Psychiatry Res 2019;272:540-50.
|
33. |
Takagi M. Toll-like receptor. J Clin Exp Hematopathol2011;51:77-92.
|
34. |
Lavelle EC, Murphy C, O'Neill L, Creagh EM. The role of TLRs, NLRs, and RLRs in mucosal innate immunity and homeostasis. Mucosal Immunol 2010;3:17-28.
|
35. |
Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 2007;7:1271-85.
|
36. |
Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 2005;54:1182-93.
|
37. |
Szebeni B, Veres G, Dezsofi A, Rusai K, Vannay A, Mraz M, et al. Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease. Clin ExpImmunol 2008;151:34-41.
|
38. |
Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol 2010;11:373-84.
|
39. |
Öhman L, Lindmark A-C, Isaksson S, Posserud I, Strid H, Sjövall H, et al. Increased TLR2 expression on blood monocytes in irritable bowel syndrome patients. Eur J Gastroenterol Hepatol 2012;24:398-405.
|
40. |
Fan Y, Liu B. Expression of toll-like receptors in the mucosa of patients with ulcerative colitis. Exp Ther Med 2015;9:1455-9.
|
41. |
Tan Y, Zou K-f, Qian W, Chen S, Hou X-h. Expression and implication of toll-like receptors TLR2, TLR4 and TLR9 in colonic mucosa of patients with ulcerative colitis. J Huazhong Univ Sci Technol Med Sci 2014;34:785-90.
|
42. |
Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;68:7010-7.
|
43. |
Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev 2006;212:256-71.
|
44. |
Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EM. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011;106:329-36.
|